Summary of Conference Call Company Overview - The discussion revolves around Oscar Health, a health insurance company, focusing on its performance in 2025 and expectations for 2026 [2][5]. Key Points 2025 Performance and 2026 Outlook - 2025 was a challenging year for Oscar and the broader marketplace due to misestimations of market morbidity, leading to losses [2]. - For 2026, Oscar has prepared for market shrinkage, expecting a decrease in membership from 3.4 million to approximately 3 million due to passively enrolled members not making payments [3][4]. - The company has priced for risks associated with market morbidity, anticipating a shrinkage in the 20%-30% range, but now expects it to be closer to 20% [3][4]. Membership and Retention - Oscar ended the open enrollment period with about 3.4 million members and expects to start the second quarter with around 3 million [2][3]. - The company has seen strong retention rates compared to peers, attributed to proactive measures taken over the past two years, including aggressive distribution engagement and strong plan designs [7][9]. Risk Management and Profitability - Oscar has implemented tools to assess risk scores for new members, which generally tend to be younger and healthier, leading to better profitability profiles in year two compared to year one [20][26]. - The company anticipates that the risk adjustment will be higher in the first half of the year, contributing to a 20% of premium revenue, compared to 18.5% the previous year [30]. Market Dynamics and Regulatory Environment - The marketplace is expected to shrink from approximately 24 million to 20 million members, with Oscar's peers experiencing greater attrition [6]. - Oscar has factored in potential impacts from regulatory changes and integrity measures introduced by CMS, which are expected to be implemented mid-year [34][43]. Metal Tier Changes - The company has shifted its membership mix from predominantly Silver plans to a more balanced distribution among Bronze, Silver, and Gold plans, with a significant increase in Gold plan enrollments [61][66]. - Historical performance metrics may not apply due to this shift in membership dynamics [64]. Individual Coverage Health Reimbursement Arrangement (ICHRA) - ICHRA allows employees to choose their health plans using employer-provided funds, promoting individualization and choice in healthcare [70][72]. - The tax treatment for ICHRA subsidies is favorable for both employees and employers, potentially leading to increased adoption in the future [74]. Financial Preparedness - Oscar has raised $400 million to prepare for growth and has established a $475 million revolver with top-tier banks, ensuring sufficient capital for expansion [95][96]. - The company utilizes quota share reinsurance, which covers approximately 55% of the capital required based on premiums, enhancing financial stability [97]. Cost Trends - The company experienced a per-member decline in medical costs in the latter part of the previous year, but anticipates a 12% trend in medical expenses for 2026 due to market morbidity and other factors [99][104]. Additional Insights - Oscar's proactive approach to risk management and market engagement positions it favorably compared to competitors, with a focus on maintaining a healthy member base and adapting to regulatory changes [7][34][43].

Summary of Edwards Lifesciences FY Conference Call Company Overview - **Company**: Edwards Lifesciences (NYSE: EW) - **Industry**: Medical Devices, specifically focusing on heart valve therapies Key Points Executive Transition and Succession Planning - The company is undergoing an external search for a new CFO, with a focus on ensuring a smooth transition and maintaining a strong executive team [6][7] - The leadership transition is seen positively, with a deep bench of talent within the organization [8] TAVR Franchise and Market Position - Edwards maintains a dominant share in the U.S. TAVR (Transcatheter Aortic Valve Replacement) market, with a renewed focus on the treatment of aortic stenosis [9][11] - Recent clinical data, including 7-year durability data for the SAPIEN platform, has reinforced the efficacy and safety of TAVR, leading to increased market growth and adoption [12][18] - The company expects TAVR full-year growth rates of 6%-8% for 2026, with a focus on increasing patient access rather than just market share [18][43] Asymptomatic Patient Adoption - The approval for asymptomatic patients has been a significant development, with guidelines evolving to promote earlier treatment [22][23] - The EARLY TAVR trial demonstrated that symptoms are not a prerequisite for treatment, which is expected to increase patient referrals and treatment rates [21][24] - The company is optimistic about the potential for asymptomatic patients to contribute to overall market growth once national coverage decisions (NCD) are finalized [34][36] Product Development and Innovation - The SAPIEN 3 Ultra RESILIA valve is highlighted as a key innovation, with ongoing global rollout and positive clinical trial results [16][32] - Edwards is committed to continuous innovation, with next-generation products like SAPIEN X4 in development [16][50] - The company is also focused on expanding its transcatheter mitral and tricuspid therapies (TMDT), aiming for $2 billion in sales by 2030 [44][50] Financial Performance and Profitability - The company anticipates operating margin expansion of 50-100 basis points annually, driven by lower growth rates in expenses compared to sales [40][41] - TMDT generated $545 million in sales in 2025, with expectations of $740 million to $780 million in 2026 [39][40] - The focus remains on maintaining profitability while investing in growth across various platforms [39][43] Market Competition and Strategy - Edwards is positioned as a leader in structural heart care, with a focus on providing a range of treatment options for mitral and tricuspid regurgitation [50] - The company acknowledges the presence of competition but emphasizes its commitment to addressing patient needs rather than competing with other companies [51] Recent Developments and External Factors - The company is monitoring geopolitical events, particularly in the Middle East, to ensure the safety of employees and the availability of therapies in the region [56][57] Additional Insights - The transition from a watchful waiting approach to proactive treatment for severe aortic stenosis is a critical shift in clinical practice [22][29] - The success of the EVOQUE product for tricuspid regurgitation is promising, with positive early results and significant patient outcomes [53][54] This summary encapsulates the key discussions and insights from the Edwards Lifesciences FY Conference Call, highlighting the company's strategic direction, market positioning, and future growth opportunities.

American Integrity Insurance Group (NYSE:AII) FY Conference March 02, 2026 09:50 AM ET Company ParticipantsBen Lurie - Chief Financial OfficerGreg Peters - Managing Director of Equity ResearchJon Ritchie - PresidentGreg PetersOkay, good morning, everyone, and thank you again for being here at the 47th Annual Raymond James Institutional Investors Conference. You know, one of the things that has made this conference so great through the years is the opportunity to rotate in new companies, new ideas, along wit ...

Recursion Pharmaceuticals FY Conference Summary Company Overview - **Company**: Recursion Pharmaceuticals (NasdaqGS:RXRX) - **Date of Conference**: March 02, 2026 - **Key Speaker**: Ben Taylor, CFO Key Points Industry and Company Evolution - Recursion has transitioned from a single-point solution company to an integrated platform and business model over the last 18 months, enhancing its capabilities in drug discovery and development [2][3] - The platform now includes inductive phenotypic screening, transcriptomics, proteomics, and reverse genetics, aiming to improve predictive modeling and reduce clinical trial failure rates [2][3] Financial Performance and Business Model - The company has surpassed $500 million in partnership inflows, significantly contributing to its platform development and overall value [4] - Recursion has five clinical programs and two preclinical programs, employing a risk-diversified approach across various indications and technologies [4][5] Leadership and Strategic Focus - Under CEO Najat Khan's leadership, the company emphasizes disciplined investment in high-potential areas, reducing gross spend from $606 million to $400 million while expanding capabilities [7][8] - The focus is on making data-driven decisions to prioritize projects with clear clinical or commercial pathways [8] Partnerships and Collaborations - Recursion has established significant partnerships, notably with Roche and Sanofi, generating $210 million from Roche for developing novel phenomaps in neuroscience [12][13] - The company aims to structure partnerships to cover direct development costs and achieve early milestones, leading to potential profit as operational obligations are fulfilled [14][16] Data and Technology Utilization - Recursion possesses over 50 petabytes of proprietary data, which is crucial for machine learning and AI applications in drug discovery [17] - The company is focused on addressing the 90% of biology that lacks approved drugs, utilizing innovative data creation and modeling techniques [17][18] Clinical Pipeline Updates - **REC-4881**: Demonstrated significant reductions in polyp count for patients with a genetic predisposition to cancerous polyps, with ongoing discussions with the FDA regarding the regulatory path [26][28] - **CDK7**: Initial data from ovarian cancer trials is expected in the first half of 2027, with a focus on combination therapies [48] Enrollment and Trial Efficiency - The new ClinTech platform has improved patient enrollment rates by 30%-50%, enhancing the efficiency of clinical trials [32][33] - The company is leveraging real-world data to identify optimal patient populations for trials, potentially leading to faster and more effective drug development [33][34] Future Outlook and Strategic Decisions - Recursion employs a go/no-go strategy for its pipeline, ensuring that only projects meeting specific success metrics continue to receive investment [52][54] - The company is positioned to manage its burn rate effectively while exploring out-licensing opportunities if multiple drugs succeed [53] Investor Perception and Value Proposition - There is a disconnect between investor perceptions of Recursion as a single-point solution company and its current integrated platform approach [59] - The value of partnerships and the diversified risk across the pipeline are critical aspects that investors need to understand [60] Conclusion Recursion Pharmaceuticals is evolving into a comprehensive drug discovery platform, leveraging advanced data analytics and strategic partnerships to enhance its clinical pipeline and operational efficiency. The company's focus on disciplined investment and risk diversification positions it well for future growth in the biotech industry.

Summary of PTC Therapeutics FY Conference Call (March 02, 2026) Company Overview - **Company**: PTC Therapeutics (NasdaqGS:PTCT) - **Industry**: Biotechnology, focusing on rare diseases and RNA-targeted therapies Key Highlights from 2025 and Early 2026 - **Sephience Launch**: - First approvals and global launch for Sephience for patients with Phenylketonuria (PKU) achieved in the U.S., Europe, and Japan within six months, generating over **$111 million** in revenue in the first 5.5 months [2][5] - Sephience is viewed as a **multi-billion dollar** opportunity, with expectations of reaching **$2 billion** in global sales [5][31] - **Financial Position**: - Closed 2025 with **$1.95 billion** in cash, providing flexibility and protection against uncertainties [3] - Operating expenses (OpEx) came in below guidance, with potential to reach cash flow break-even in 2026 [6][36] Sephience Market Penetration - **Patient Demographics**: - Early uptake includes a broad range of patient subtypes, including therapy-naive patients and those who have failed previous treatments [8][11] - The total addressable market in the U.S. is approximately **17,000** patients with PKU [9] - **Centers of Excellence**: - Over **80%** of centers of excellence have initiated at least one patient on Sephience, indicating strong early penetration [10] - **Patient Retention**: - Early refill rates are high, with low discontinuation rates in the low single digits, suggesting strong adherence to the therapy [16][17] Competitive Landscape - **Market Dynamics**: - There are misconceptions about the need for patients to fail on generic Kuvan before accessing Sephience; however, no step edits have been observed in payer policies [21] - The company is not currently worried about competition, as it believes Sephience will establish itself as the standard of care [39] International Expansion - **Global Strategy**: - Launch in Germany has shown early interest, with pricing and reimbursement processes underway [23] - Japan is prioritized as a high-value market, with expectations for launch in early Q2 2026 [24] - The company is also exploring opportunities in Brazil and other regions, including the Middle East and North Africa [27] Financial Guidance and Future Outlook - **Revenue Guidance**: - The majority of 2026 revenue is expected to come from Sephience, with a potential decline in revenue from more mature products due to increased competition [32][34] - **Long-term Vision**: - The company aims for cash flow break-even in 2026 and has IP protection extending to **2039**, indicating a long-term growth strategy [31][36] R&D Pipeline and Future Developments - **Ongoing Programs**: - Continued advancement in R&D, particularly in RNA splicing and inflammation platforms [5][62] - Excitement around the MSH3 program and NLRP3 program, with plans to move into clinical trials soon [62] Conclusion - PTC Therapeutics is positioned strongly in the biotechnology sector with a successful launch of Sephience, a robust financial position, and a promising pipeline of therapies. The company is focused on expanding its market presence while maintaining operational efficiency and preparing for future growth opportunities.

Summary of Apellis Pharmaceuticals FY Conference Call Company Overview - **Company**: Apellis Pharmaceuticals (NasdaqGS:APLS) - **Key Products**: SYFOVRE and EMPAVELI - **Focus Areas**: Geographic atrophy, C3G, IC-MPGN, and gene editing programs Core Points and Arguments Business Strategy and Strengths - Apellis has established a strong foundation with three main pillars: SYFOVRE, EMPAVELI, and a gene editing program in collaboration with Beam [2][4] - SYFOVRE is positioned as a best-in-class therapy for geographic atrophy, with ongoing development of a combination therapy using siRNA against C3 [2] - EMPAVELI is experiencing a strong launch, with over 5% penetration in the C3G and IC-MPGN market, targeting a potential 50% penetration at peak [3][6][35] Revenue Performance - Revenue declined year-over-year due to unique factors, including flat revenue from EMPAVELI's initial indication (PNH) and challenges faced by SYFOVRE [5][10] - The decline was attributed to the loss of patient co-pay assistance, leading to treatment discontinuation and a shift to less effective therapies [7][8] - Despite these challenges, there was a 17% growth in injections for geographic atrophy, indicating underlying demand [9] Market Dynamics - SYFOVRE's market share has remained stable at approximately 60%, with a 50/50 split for new patient enrollments [18] - The introduction of a prefilled syringe is expected to enhance market penetration and ease of administration [14] - The retina community is increasingly recognizing the importance of SYFOVRE, especially with new data showing significant benefits for patients [13] Competitive Landscape - Apellis believes SYFOVRE has a superior efficacy profile compared to competitors, supported by robust data from clinical trials [20][21] - EMPAVELI is the only product approved for pediatric use and post-transplant patients, differentiating it from competitors [31] - Safety profile of EMPAVELI is strong, with no cases of encapsulated meningococcal infection reported despite expectations based on class effects [32] Future Outlook - Apellis aims to achieve profitability with a solid cash position of $466 million, bolstered by expected milestone payments [44] - The company projects significant revenue growth, with expectations of reaching $1.7 billion by 2030 [47] - Upcoming data readouts from clinical trials, particularly for the gene editing program, are anticipated to drive future growth [42] Additional Important Insights - The company is focused on redefining treatment for geographic atrophy and addressing the unmet needs in the wet AMD market, which is valued at $12 billion [26] - The potential for EMPAVELI in FSGS and DGF is significant, with a combined epidemiology of approximately 33,000 patients in the U.S. [35][36] - The company is committed to continuous improvement in patient treatment experiences and outcomes, leveraging innovative technologies like functional OCT [15][16] This summary encapsulates the key points discussed during the Apellis Pharmaceuticals FY Conference Call, highlighting the company's strategic direction, market performance, and future growth potential.

Winnebago Industries FY Conference Summary Company Overview - **Company**: Winnebago Industries (NYSE: WGO) - **Industry**: Outdoor recreation, specifically RVs and powerboats - **Brands**: Winnebago, Grand Design, Newmar, Barletta, Chris-Craft - **Headquarters**: Minnesota, with operations in Iowa, Indiana, and Florida - **Revenue**: Approximately $2.9 billion on a trailing twelve-month basis - **Employees**: 5,200 [4][5] Key Financial Metrics - **Growth**: Revenue increased from $1 billion in 2016 to nearly $3 billion, peaking at $5 billion during COVID - **Market Share**: Increased from 3% to over 10% in the RV market - **Revenue Breakdown**: Approximately 42-43% from motorhomes, 15% from marine business [5][7] Strategic Focus - **Enterprise Strategies**: - Attracting top talent - Building a premium portfolio of brands - Enhancing customer experience through digital capabilities - Driving operational excellence and synergy across brands [6][11] Industry Insights - **Market Sentiment**: Mixed signals from recent RV and marine shows; optimism exists but lacks clear trends - **Selling Season**: Anticipated to start mid to late March; recent months showed weaker retail performance [14][15] - **Affordability Concerns**: Rising interest rates and price increases have shifted consumer preferences towards lower-priced options, impacting Winnebago's premium positioning [16][20] Inventory and Promotional Environment - **Inventory Levels**: Improved quality and absolute levels of inventory for towables and motorhomes; marine inventory still needs work [29][30] - **Promotional Activity**: Consistent year-over-year; pressure remains from affordability-minded consumers [31][34] Brand Performance - **Winnebago Brand**: Facing challenges due to misalignment with market trends; undergoing leadership changes and product portfolio renovations [44][51] - **Grand Design**: Strong performance with new product introductions and a market share of 4% in the motorhome segment [68] - **Newmar**: Expanding into the Super C market; introducing new Class C models to meet customer demand for smaller, high-quality options [76][80] - **Barletta**: Achieved around 10% market share in the aluminum pontoon market; expanding product portfolio with new affordable options [98][100] Capital Allocation and Debt Management - **Leverage Ratio**: Targeting a net leverage ratio of 0.9-1.5; currently at 2.7, with a goal to reduce to 2.0 by the end of fiscal 2026 [10][111] - **Debt Reduction**: Recent paydown of $100 million in high-yield notes to improve leverage position [112] - **M&A Strategy**: Focused on improving balance sheet before pursuing acquisitions; marine market seen as a more fragmented opportunity compared to RV [115][118] Future Outlook - **Market Recovery**: Anticipated recovery in the RV market, with a more delayed recovery expected in the marine sector [86][88] - **Product Development**: Continued focus on expanding product lines and enhancing dealer relationships, particularly for Barletta and Grand Design [91][96] Conclusion - Winnebago Industries is navigating a mixed market environment with strategic initiatives aimed at enhancing brand performance and operational efficiency. The company is focused on debt reduction and capital allocation while preparing for a potential recovery in the RV and marine markets.

Summary of Insmed Fireside Chat at TD Cowen Healthcare Conference Company Overview - **Company**: Insmed - **Key Product**: BRINSUPRI, a treatment for bronchiectasis Key Industry Insights - **Market Dynamics**: The bronchiectasis market is currently underserved, with Insmed targeting 250,000 patients diagnosed with two or more exacerbations, which could lead to peak sales exceeding $5 billion [27][28][65] - **Patient Experience**: Positive patient experiences with BRINSUPRI are crucial for driving repeat prescriptions from physicians. Anecdotal evidence suggests significant improvements in patients' quality of life [25][26][40] Financial Performance - **Q4 Revenue**: Insmed reported Q4 revenue of $144 million, significantly exceeding both buy-side and sell-side consensus estimates [6][7] - **Future Projections**: Initial revenue guidance for the upcoming quarters has been revised upwards, with estimates now exceeding $1 billion, driven by strong physician engagement and patient feedback [34][37][40] Launch Strategy - **Physician Engagement**: Insmed has engaged over 4,000 physicians, with a focus on expanding the breadth and depth of prescribing behavior. Half of these physicians have only written one prescription, indicating potential for growth as they receive positive feedback from patients [7][8][40][42] - **Market Access**: Insmed is working with insurance companies to streamline access for patients, particularly those with two or more exacerbations. The company has offered modest discounts to facilitate policy shaping [50][61] Competitive Landscape - **ARIKAYCE**: Insmed has been selling ARIKAYCE for eight years, which has a challenging administration process. In contrast, BRINSUPRI is a once-daily pill with a favorable safety profile, making it easier to prescribe [23][24] - **TPIP Development**: Insmed is developing TPIP, a once-daily inhaled treatment for pulmonary arterial hypertension (PAH). The competitive landscape is evolving, but Insmed believes TPIP's profile remains strong against emerging products [66][67] Regulatory and Market Challenges - **MFN Policy**: Insmed is monitoring the Most Favored Nation (MFN) policy, which could impact pricing strategies in the U.S. market. The company is cautious but optimistic about navigating these regulatory challenges [46][48] - **Insurance Coverage**: The company is addressing payer access and reimbursement hurdles, with a focus on simplifying the attestation process for patients with two or more exacerbations [50][51] Research and Development - **ENCORE Study**: The upcoming ENCORE study for ARIKAYCE could significantly increase the addressable market, potentially doubling the current target population [82][86] - **Patient Outcomes**: Insmed is focused on demonstrating durable culture conversion in patients, which is critical for gaining physician trust and expanding usage [97][98] Conclusion - Insmed is positioned for growth with BRINSUPRI, leveraging positive patient experiences and strong physician engagement. The company is navigating market access challenges while preparing for significant upcoming studies that could expand its market presence.

Summary of Mid-America Apartment Communities (MAA) Conference Call Company Overview - **Company**: Mid-America Apartment Communities (NYSE: MAA) - **Type**: Multifamily Real Estate Investment Trust (REIT) - **Focus Area**: Predominantly in the Sun Belt region of the U.S. with over 30 years of experience in the area [2][3] Key Points and Arguments Investment Value - **Current Value Proposition**: MAA offers a portfolio with strong Core FFO (Funds From Operations) and TSR (Total Shareholder Return) performance at lower volatility compared to peers [4] - **Market Position**: MAA has the largest exposure to high-demand, high-growth regions, with one of the lowest multiples and highest cap rates seen in recent times [4] - **Dividend Yield**: The company provides a strong current income supported by an A-rated balance sheet [5] Growth Prospects - **Supply Dynamics**: There is a significant reduction in new supply, with 30% fewer deliveries expected in 2026 compared to the previous year [11] - **Demand Fundamentals**: Strong job growth, population growth, household formation, and wage growth are driving demand, particularly in the Sun Belt region [5][11] - **Renewal Rates**: Expected renewal lease-over-lease rates are consistent at over 5%, with a positive outlook for demand expectations [10][24] Market Trends - **Leasing Activity**: Early indicators show a positive trend in leasing activity, with a blended pricing expectation of 1%-1.5% for 2026 [9][10] - **Occupancy Rates**: Market-level occupancies are about 200 basis points higher than previous lows, indicating a recovery in demand [19] - **Concessions**: While some concessions are still present in the market, they are expected to burn off, creating opportunities for lease growth [20] Regional Insights - **Strong Markets**: Dallas and Atlanta are highlighted as markets showing early signs of pricing power, while Austin and Phoenix are lagging [21][22] - **Challenging Markets**: Raleigh and Charlotte are experiencing downward trends due to increased supply [23] Development and Capital Allocation - **Development Pipeline**: MAA is conservative in underwriting developments, with expected yields in the 6%-6.5% range. However, the full earnings contribution from current developments is delayed by about a year [50][51] - **Stock Buybacks**: MAA has been cautious with stock buybacks, focusing on long-term TSR performance through development rather than aggressive repurchases [56] Technological Integration - **AI Deployment**: MAA is actively using AI for lead management and operational efficiencies, with plans to build proprietary AI capabilities to enhance data mining [64][66] Economic and Regulatory Environment - **Affordability Trends**: Rent-to-income ratios have improved, with current ratios at 20%, down from 23% two years ago, indicating a more affordable product [40] - **Legislative Impact**: Current proposals regarding housing affordability are not expected to significantly change turnover rates or demand dynamics [36][38] Additional Important Insights - **Demographic Shifts**: The average resident is slightly older and more financially stable, with a significant portion being single [41] - **Construction Costs**: A slight reduction in construction costs (around 5%) has been observed, but substantial reductions are needed to stimulate new supply [43][44] This summary encapsulates the key insights and data points from the conference call, providing a comprehensive overview of MAA's current position and future outlook in the multifamily real estate market.

Summary of EastGroup Properties (NYSE: EGP) 2026 Conference Call Company Overview - **Company**: EastGroup Properties - **Type**: Shallow-bay industrial REIT - **Focus**: Smaller infill buildings, primarily in high-growth "Smile States" where population is increasing [7][8] Key Financial Performance - **FFO Growth**: 51 consecutive quarters of FFO growth compared to the same quarter of the prior year [8] - **Same-Store NOI**: Positive growth for nearly 13 years [8] - **Debt Metrics**: - Debt to EBITDA: Approximately 3 times, the lowest in the sector [10] - Debt to total market cap: Around 14% [10] - **Tenant Diversity**: Top 10 tenants contribute less than 7% of revenue, indicating strong geographic and tenant diversification [10] Market Position and Strategy - **Market Dynamics**: - Supply of shallow-bay buildings is at its lowest since 2018, with vacancy rates significantly lower than the overall industrial market [14] - Average tenancy size is about 35,000 square feet, with average building size just under 100,000 square feet [14] - **Leasing Activity**: - Development leasing has picked up, with 166,000 square feet signed recently [15] - The company is optimistic about continued leasing activity, with a focus on long-term tenants [15][18] Development and Construction Insights - **Development Yields**: Consistent yields around 7%, with a strategy to build in phases based on market demand [42][44] - **Construction Costs**: Lower construction costs observed due to reduced demand for new development [52] - **Land Inventory**: Over 1,000 acres of fully entitled land available for future development [48] Economic and Regulatory Environment - **Impact of Tariffs**: Uncertainty remains regarding tariffs, but tenants are adapting to market conditions [28][32] - **Cap Rates**: Vary by market, with lower cap rates in stronger markets like Nashville and Dallas, generally in the low to mid-5% range [33][34] Future Outlook - **Leasing Cadence**: Difficult to predict, but the company is prepared to respond quickly to tenant needs [59][61] - **AI and Technology**: Investments in technology to enhance productivity and efficiency, particularly in accounting processes [64][66] - **M&A Landscape**: Anticipation of fewer companies in the REIT industry in the coming year [69] Additional Insights - **Tenant Pool**: Focus on metropolitan areas with growth potential, such as Orlando, Dallas, Austin, and Phoenix [23] - **Market Resilience**: Despite economic fluctuations, the company has maintained a strong occupancy rate, with 97% leased at year-end [30] This summary encapsulates the key points discussed during the EastGroup Properties conference call, highlighting the company's financial performance, market strategy, development insights, and future outlook.